Chrysos (C79) AGM 2025 Presentation summary

Operational performance and market activity

• PhotonAssay sample volumes are nearing 1,000,000 per month, with consistent year-over-year growth of 50-100%.

• YTD unaudited revenue is $28.9m, with additional assay charges now representing 26.4% of revenue.

• 41 PhotonAssay units are deployed globally, with recent and upcoming installations in key mining regions.

• Four new installations and two new lease agreements highlight strong global demand and customer diversification.

• Industry outlook remains positive, supported by strong gold prices and robust exploration and production activity.

Financial highlights and guidance

• FY26 revenue guidance is $80m to $90m, with EBITDA expected between $20m and $27m.

• Cash on hand is $26.7m, with $46m drawn from a $95m debt facility, ensuring funding for further unit growth.

• Record sample volumes continue to underpin revenue growth.

Technology development and innovation

• Next-generation PhotonAssay units (XC and XN) feature improved automation, reliability, and ease of use.

• RAFT project enhances measurement accuracy and user experience, with retrofittable upgrades for existing units.

• Ongoing R&D focuses on expanding assay capabilities to new elements and integrating complementary technologies like XRF and NAA.

• Automated sample preparation solutions are being implemented to further streamline laboratory operations.